Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
infectious disease
Biotech
Moderna scraps congenital virus program after vax fails ph. 3
While the mRNA-1647 vaccine was well-tolerated, Moderna said, the shot’s ability to prevent infection was well below the company’s target.
Darren Incorvaia
Oct 22, 2025 5:15pm
As measles surges, the first treatment remains a pipe dream
Jul 17, 2025 2:02pm
Shionogi offers $600M for Swiss biotech's antibiotic program
Jul 2, 2025 1:00am
GSK snags longtime Sanofi exec to lead vaccine development
Jun 9, 2025 10:45am
GSK's bet on rejected UTI antibiotic pays off with phase 3 win
May 28, 2025 8:42am
Fierce Healthcare
Court blocks HHS RIF again after Trump's Supreme Court appeal
May 23, 2025 10:30am